Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | FABP3 | P05413 | 1/20 | 0.30 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.30 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2227454 | 0.84 | ALDH1A1 (0.39) | PARP1EGLN1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5860460 | 0.74 | LMNA (0.49) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1486017 | 0.74 | TYMP (0.33) | MEN1KMT2A | |
| SCHEMBL5796882 | 0.72 | KDM4E (0.41) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4348692 | 0.70 | ADRA1D (0.37) | MEN1KMT2A | |
| SCHEMBL6537411 | 0.70 | KMO (0.36) | SMN1; SMN2ALDH1A1GRIK1GRIA1 | |
| SCHEMBL4347789 | 0.70 | TYMP (0.31) | — | |
| SCHEMBL13629866 | 0.69 | PDE4A (0.36) | SMN1; SMN2APEX1CA2KDM4EALDH1A1 | |
| SCHEMBL5282402 | 0.69 | GRIA1 (0.51) | MEN1KMT2AKDM4EALDH1A1GRIK1 | |
| SCHEMBL667246 | 0.69 | KDM4E (0.54) | KMT2ASMN1; SMN2KDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3651774-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS OF USEIN VIVO | The Scripps Research Institute (US) | 2020-05-20 | — | — | EP | claimed |
| WO-2019014262-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS OF USE IN VIVO THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-17 | — | — | WO | claimed |
| US-20150211004-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-30 | — | — | US | claimed |
| EP-2838541-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | Agency For Science, Technology And Research (SG) | 2015-02-25 | — | — | EP | claimed |
| WO-2013158046-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-24 | — | — | WO | claimed |
| US-20250340937-A1 | COLORECTAL CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | CHRONIX BIOMEDICAL (US) | 2025-11-06 | — | — | US | disclosed |
| US-12359252-B2 | Colorectal cancer associated circulating nucleic acid biomarkers | CHRONIX BIOMEDICAL (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240401120-A1 | METHODS FOR BIAS-FREE QUANTIFICATION OF RNA | CHRONIX BIOMEDICAL (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024220570-A2 | C3D IMMUNOTHERAPIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-4409031-A1 | METHODS FOR BIAS-FREE QUANTIFICATION OF RNA | Chronix Biomedical (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240070422-A1 | Methods of Storing Information Using Nucleic Acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-02-29 | — | — | US | disclosed |
| WO-2024022495-A1 | Anti-MerTK ANTIBODIES AND USES THEREOF | CONCEPT TO MEDICINE BIOTECH CO., LTD. (CN) | 2024-02-01 | — | — | WO | disclosed |
| WO-2001089556-A1 | INHIBITION OF SMAD3 TO PREVENT FIBROSIS AND IMPROVE WOUND HEALING | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001086002-A2 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF PSORIASIS | GENETICS INSTITUTE, LLC (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001045494-A2 | PYROPHOSPHATASE STRESS-RELATED PROTEINS AND METHODS OF USE IN PLANTS | BASF PLANT SCIENCE GMBH (DE) | 2001-06-28 | — | — | WO | disclosed |
| EP-1109908-A2 | LEPTIN INDUCED GENES | Millennium Pharmaceuticals, Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1086213-A2 | HUMAN GENES DIFFERENTIALLY EXPRESSED IN COLON CANCER | Bayer Corporation (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2001000878-A2 | A NOVEL VASCULAR ENDOTHELIAL GROWTH FACTOR FAMILY MEMBER AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000015826-A2 | LEPTIN INDUCED GENES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-1999064576-A2 | HUMAN GENES DIFFERENTIALLY EXPRESSED IN COLON CANCER | BAYER CORPORATION (US) | 1999-12-16 | — | — | WO | disclosed |